FDG PET/CT in Immune-Related Arthritis in a Patient Treated With Nivolumab.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 36252811.
- Also identified by DOI 10.1097/RLU.0000000000004429.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint inhibitors are a new and different treatment option in many of solid tumors, but with many recognized immune-related adverse side effects. In this interesting image, we are presenting a 56-year-old woman with primary malignant melanoma who underwent nivolumab therapy for 5 months, and a posttreatment whole-body FDG PET/CT scan for treatment response evaluation demonstrated increased metabolic activity in the entire major joints of the upper and lower extremities. This was a new finding compared with previous FDG PET/CT scan and was interpreted as an immune-related arthritis complication.
Medical subject headings
- Melanoma
- Arthritis